Appeal No. 2000-1812
Application No. 08/432,483
Background
As background to this invention the applicant, at pages 2-4 of the specification
explains that it is known that cholesteryl ester transport protein (CETP) is known to
mediate the transfer of cholesteryl esters from high density lipoproteins (HDL) to
triglyceride-rich lipoproteins such as very low density lipoproteins (VLDL) and low density
lipoproteins (LDL) and also the reciprocal exchange of triglycerides from VLDL to HDL. It
is suggested that CETP may play a role in modulating the levels of cholesteryl esters and
triglycerides associated with various classes of lipoproteins. It has apparently been
established that a high CETP cholesteryl ester transfer activity has been correlated with
increased levels of LDL-associated cholesterol and VLDL-associated cholesterol which is
in turn correlated with increase risk of cardiovascular disease. Similarly, decreased
susceptibility to cardiovascular disease, such as atherosclerosis is generally correlated
with increased absolute levels of circulating HDL and increased levels of HDL relative to
circulating levels of lower density lipoproteins such as VLDL and LDL. Thus, applicant
explains that increased levels of cholesteryl ester transfer activity can produce a decrease
in HDL levels relative to LDL and VLDL levels which is correlatable with an increased risk
of atherosclerosis. Appellant describes the claimed invention at page 6 of the
Specification as being directed to compounds and methods useful for modulation or
inhibition of cholesteryl ester transfer protein activity, using vaccine peptides which when
2(...continued)
maintained the all grounds of rejection, it is can be presumed that the examiner did not find
either the arguments or additional evidence persuasive of error in the rejections presented
in the Examiner's Answer.
4
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 Next
Last modified: November 3, 2007